Market Eyes LiveNovo-Nordisk A/S (NVO) Stock Rating & Analysis
MELANY's data-driven read on Novo-Nordisk A/S.
Novo Nordisk, headquartered in Denmark, is the world's leading provider of diabetes care products and holds roughly one-third of the global branded diabetes treatment market. It develops and sells human and modern insulins, injectable diabetes therapies including GLP-1 treatments, oral antidiabetic agents, and obesity treatments, plus a biopharmaceutical segment (under 10% of revenue) focused on protein therapies for hemophilia and other disorders.
Why NVO scores 67/100
MELANY scores Novo-Nordisk A/S 67/100 by weighing eight factors. Here is how NVO breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 11.8x vs sector 22.0x median
- FCF yield 17.9%
Margins, returns on capital, and balance-sheet strength.
- Gross margin 82%
- ROE 60%
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for NVO
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Novo-Nordisk A/S sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 66/100 for strength. Theme strength feeds NVO's momentum and catalyst factors above.
NVO trade plan (members only)
MELANY has a full position plan for Novo-Nordisk A/S: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates NVO
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Novo-Nordisk A/S's 67/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about NVO
Is Novo-Nordisk A/S (NVO) a buy?
As of 2026-08-10, MELANY rated Novo-Nordisk A/S Favorable with a composite score of 67/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Novo-Nordisk A/S's MELANY score?
Novo-Nordisk A/S (NVO) has a MELANY composite score of 67/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the NVO stock rating calculated?
MELANY scores NVO from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Novo-Nordisk A/S stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Novo-Nordisk A/S (NVO) Favorable with a composite of 67/100 as of 2026-08-10. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the NVO stock price forecast?
MELANY does not publish price targets or forecasts for NVO. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 67/100 across eight factors for Novo-Nordisk A/S, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is NVO stock overvalued or undervalued?
MELANY's valuation factor currently reads 62/100 for Novo-Nordisk A/S, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives NVO's read.
What price should I buy NVO at?
Rather than chasing the current price, MELANY computes a smart entry zone for NVO: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying NVO stock?
The top risks MELANY currently flags for Novo-Nordisk A/S: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Novo-Nordisk A/S a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 95/100 for Novo-Nordisk A/S, and earnings track record, at 63/100. The 67/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will NVO stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 55/100 for NVO right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this NVO rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-10. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores NVO continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
NVO's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.